697 related articles for article (PubMed ID: 17698862)
1. Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?
Hanauer SB
Gut; 2007 Sep; 56(9):1181-3. PubMed ID: 17698862
[TBL] [Abstract][Full Text] [Related]
2. Anti-TNF therapy in inflammatory bowel diseases: a huge review.
Peyrin-Biroulet L
Minerva Gastroenterol Dietol; 2010 Jun; 56(2):233-43. PubMed ID: 20485259
[TBL] [Abstract][Full Text] [Related]
3. Review article: Infliximab therapy for inflammatory bowel disease--seven years on.
Rutgeerts P; Van Assche G; Vermeire S
Aliment Pharmacol Ther; 2006 Feb; 23(4):451-63. PubMed ID: 16441465
[TBL] [Abstract][Full Text] [Related]
4. [Biological therapy as treatment of inflammatory bowel diseases].
Agnholt J
Ugeskr Laeger; 2008 Jun; 170(24):2152-6. PubMed ID: 18565302
[TBL] [Abstract][Full Text] [Related]
5. Immunosuppression in inflammatory bowel disease: traditional, biological or both?
Van Assche G; Vermeire S; Rutgeerts P
Curr Opin Gastroenterol; 2009 Jul; 25(4):323-8. PubMed ID: 19417645
[TBL] [Abstract][Full Text] [Related]
6. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy.
Sokol H; Seksik P; Carrat F; Nion-Larmurier I; Vienne A; Beaugerie L; Cosnes J
Gut; 2010 Oct; 59(10):1363-8. PubMed ID: 20587545
[TBL] [Abstract][Full Text] [Related]
7. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
[TBL] [Abstract][Full Text] [Related]
8. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?
D'Haens GR; Panaccione R; Higgins PD; Vermeire S; Gassull M; Chowers Y; Hanauer SB; Herfarth H; Hommes DW; Kamm M; Löfberg R; Quary A; Sands B; Sood A; Watermeyer G; Lashner B; Lémann M; Plevy S; Reinisch W; Schreiber S; Siegel C; Targan S; Watanabe M; Feagan B; Sandborn WJ; Colombel JF; Travis S
Am J Gastroenterol; 2011 Feb; 106(2):199-212; quiz 213. PubMed ID: 21045814
[TBL] [Abstract][Full Text] [Related]
9. Conventional treatment in inflammatory bowel disease--recent trends. Immunosuppressants and biologic agents: should they or need they be used together? How to use immunosuppressive therapy better (and safer) tomorrow?
Leung Y; Hanauer SB
Gastroenterol Clin Biol; 2009 Jun; 33 Suppl 3():S202-8. PubMed ID: 20117343
[TBL] [Abstract][Full Text] [Related]
10. Update on idiopathic colitides.
Strobel S; Abreu MT
Curr Opin Gastroenterol; 2013 Jan; 29(1):60-5. PubMed ID: 23207597
[TBL] [Abstract][Full Text] [Related]
11. [Chronic inflammatory bowel disease: Crohn's disease and ulcerative colitis].
Fiasse R; Denis MA; Dewit O
J Pharm Belg; 2010 Mar; (1):1-9. PubMed ID: 20432590
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting.
Trinder MW; Lawrance IC
J Gastroenterol Hepatol; 2009 Jul; 24(7):1252-7. PubMed ID: 19220669
[TBL] [Abstract][Full Text] [Related]
13. [Inflammatory diseases of the intestines].
Felley C; Guyot J; Hess J; Mottet C; Delarive J; Michetti P
Rev Med Suisse; 2006 Jan; 2(49):191-4, 196-8, 201-3. PubMed ID: 16493962
[TBL] [Abstract][Full Text] [Related]
14. Indoleamine 2,3-dioxygenase expression in human inflammatory bowel disease.
Zhou L; Chen H; Wen Q; Zhang Y
Eur J Gastroenterol Hepatol; 2012 Jun; 24(6):695-701. PubMed ID: 22387885
[TBL] [Abstract][Full Text] [Related]
15. Tumor necrosis factor-α monoclonal antibodies in the treatment of inflammatory bowel disease: clinical practice pharmacology.
Lee TW; Fedorak RN
Gastroenterol Clin North Am; 2010 Sep; 39(3):543-57. PubMed ID: 20951917
[TBL] [Abstract][Full Text] [Related]
16. Disease-modifying anti-inflammatory bowel disease drugs (DMAIDs): the missing term in the literature.
Peyrin-Biroulet L
Am J Gastroenterol; 2013 May; 108(5):859-60. PubMed ID: 23644972
[No Abstract] [Full Text] [Related]
17. New strategies in the management of inflammatory bowel disease.
Rutgeerts P; Baert F
Acta Clin Belg; 1999 Oct; 54(5):274-80. PubMed ID: 10555385
[TBL] [Abstract][Full Text] [Related]
18. How to improve the safety of biologic therapy in Crohn's disease.
Ferkolj I
J Physiol Pharmacol; 2009 Dec; 60 Suppl 7():67-70. PubMed ID: 20388947
[TBL] [Abstract][Full Text] [Related]
19. How to manage difficult Crohn's disease: optimum delivery of anti-TNFs.
Krygier DS; Ko HH; Bressler B
Expert Rev Gastroenterol Hepatol; 2009 Aug; 3(4):407-15. PubMed ID: 19673627
[TBL] [Abstract][Full Text] [Related]
20. [When can TNF-alpha inhibitors against inflammatory bowel disease be withdrawn?].
Moum B
Tidsskr Nor Laegeforen; 2007 Jun; 127(12):1673. PubMed ID: 17571118
[No Abstract] [Full Text] [Related]
[Next] [New Search]
